Skip to main content

Introduction

Inhibition of Tumor Promotion by Antihormonal Agents

  • Conference paper
Hormonal Carcinogenesis
  • 43 Accesses

Abstract

Hormones are regulatory substances. They stimulate, inhibit, or modulate physiological processes throughout the body. Growth and development and normal bodily functions would be impossible without these products of the endocrine system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jordan VC, Dix CJ, Allen KE (1979) The effectiveness of a long-term treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE (eds) Adjuvant therapy for cancer, II. Grune and Stratten, New York, pp 19–26.

    Google Scholar 

  2. Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer: Eight Cain Memorial Award Lecture. Cancer Res 50: 4177–4189.

    Google Scholar 

  3. Robinson SP, Maul DA, Jordan VC (1988) Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene ( DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24: 1817–1821.

    Google Scholar 

  4. Cuzik J, Baum M (1985) Tamoxifen and contralateral breast cancer. Lancet 2: 282.

    Article  Google Scholar 

  5. Forander T, Rutquist LE, Cedermark B, Glas U, Mattson A, Siljversward JD, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjolmar ML (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117–120.

    Article  Google Scholar 

  6. Lerner LJ, Holthaus FJ, Jr, Thompson CR (1958) A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxy-phenyl)-1-phenyl-2-pmethoxyphenyl ethanol. Endocrinology 63: 295–318.

    Article  PubMed  CAS  Google Scholar 

  7. Lerner LJ, Bianchi A, Borman A (1960) A-norprogesterone, an androgen antagonist. Proc Soc Exp Biol Med 103: 172–175.

    PubMed  CAS  Google Scholar 

  8. Lerner LJ (1964) Hormone antagonists. Inhibitors of specific activities of estrogen and androgen. Recent Progress in Hormone Res 20: 435–490.

    CAS  Google Scholar 

  9. Herrman W, Wyss R, Riondel A, Philbert D, Teutsch G, Sakiz E, Baulieu EE (1982) Effect d’un steriode anti-progesterone chez la femme: interruption du cycle menstruel et de las grossesse au debut. C R Acad Sci Serte III 294: 933–938.

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag New York, Inc.

About this paper

Cite this paper

Lerner, L.J. (1992). Introduction. In: Li, J.J., Nandi, S., Li, S.A. (eds) Hormonal Carcinogenesis. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9208-8_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-9208-8_16

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4613-9210-1

  • Online ISBN: 978-1-4613-9208-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics